Autologous CD5 CAR T-cells
BJGBYY-IIT-LCYJ-2024-002
Phase 2 small_molecule active
Quick answer
Autologous CD5 CAR T-cells for T-Cell Acute Lymphocytic Leukemia is a Phase 2 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- T-Cell Acute Lymphocytic Leukemia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active